A long-term, open-label trial of the safety and efficacy of etanercept (25 mg twice weekly) in patients with rheumatoid arthritis (interim analysis of 4-year data)

被引：0
|
作者：
Klareskog, L [1 ]
Wajdula, J [1 ]
Pedersen, R [1 ]
机构：
[1] Karolinska Hosp, Rheumatol Unit, S-10401 Stockholm, Sweden
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2003年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：189 / 189
页数：1
相关论文
共 50 条
  • [31] LONG-TERM SAFETY OF 4-WEEKLY CERTOLIZUMAB PEGOL IN RHEUMATOID ARTHRITIS: 5 YEAR RESULTS FROM AN OPEN LABEL EXTENSION STUDY
    Fleischmann, R.
    van Vollenhoven, R.
    Vencovsky, J.
    Alten, R.
    Davies, O.
    Stach, C.
    de Longueville, M.
    van Lunen, B.
    Choy, E.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 523 - 523
  • [32] Long-Term Safety and Efficacy of 4-Weekly Certolizumab Pegol Combination and Monotherapy in Rheumatoid Arthritis: 5 Year Results from an Open Label Extension Study
    Fleischmann, Roy M.
    van Vollenhoven, Ronald F.
    Vencovsky, Jiri
    Alten, Rieke
    Davies, Owen
    Stach, Christian
    de Longueville, Marc
    Van Lunen, Brenda
    Choy, Ernest
    [J]. ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S565 - S566
  • [33] Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs
    Kavanaugh, Arthur
    Westhovens, Rene R.
    Winthrop, Kevin L.
    Lee, Susan J.
    Tan, YingMeei
    An, Di
    Ye, Lei
    Sundy, John S.
    Besuyen, Robin
    Meuleners, Luc
    Stanislavchuk, Mykola
    Spindler, Alberto J.
    Greenwald, Maria
    Alten, Rieke
    Genovese, Mark C.
    [J]. JOURNAL OF RHEUMATOLOGY, 2021, 48 (08) : 1230 - 1238
  • [34] Longer Term Safety and Efficacy of Peficitinib in Patients with Rheumatoid Arthritis After 22.7 Months Mean Treatment Exposure: Interim Data from a Long-Term, Open-Label Extension Study in Japan, Korea and Taiwan
    Takeuchi, Tsutomu
    Tanaka, Yoshiya
    Tanaka, Sakae
    Kawakami, Atsushi
    Song, Yeong-Wook
    Chen, Yi-Hsing
    Rokuda, Mitsuhiro
    Izutsu, Hiroyuki
    Ushijima, Satoshi
    Kaneko, Yuichiro
    Nakashima, Yoshihiro
    Shiomi, Teruaki
    Yamada, Emi
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [35] ABP 501 Long-Term Safety/Efficacy: Interim Results from an Open-Label Extension Study
    Cohen, Stanley
    Pablos, Jose L.
    Zhang, Nan
    Rizzo, Warren
    Muller, Gerhard
    Padmanaban, Devi
    Kivitz, Alan
    Matsumoto, Alan K.
    Kaur, Primal
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [36] Long-term efficacy and safety of ezetimibe 10 mg in patients with homozygous sitosterolemia:: a 2-year, open-label extension study
    Luetjohann, D.
    von Bergmann, K.
    Sirah, W.
    Macdonell, G.
    Johnson-Levonas, A. O.
    Shah, A.
    Lin, J.
    Sapre, A.
    Musliner, T.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2008, 62 (10) : 1499 - 1510
  • [37] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: interim analysis of the DAYBREAK open-label extension study
    Selmaj, K. W.
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Arnold, D. L.
    Hartung, H. -P.
    Montalban, X.
    Havrdova, K.
    Hoogerheyde, J.
    Afsari, S.
    Sheffield, J. K.
    Shi, F.
    Minton, N.
    Silva, D.
    Kappos, L.
    Cohen, J. A.
    Cree, B. A. C.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 617 - 618
  • [38] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: interim analysis of the DAYBREAK open-label extension study
    Selmaj, K. W.
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Arnold, D. L.
    Hartung, H. -P.
    Montalban, X.
    Havrdova, E. K.
    Krakovich, A.
    Sheffield, J. K.
    Cheng, C. -Y.
    Minton, N.
    Silva, D.
    Kappos, L.
    Cohen, J. A.
    Cree, B. A. C.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 359 - 360
  • [39] Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial
    Blauvelt, Andrew
    Langley, Richard G.
    Lacour, Jean-Philippe
    Toth, Darryl
    Laquer, Vivian
    Beissert, Stefan
    Wollenberg, Andreas
    Herranz, Pedro
    Pink, Andrew E.
    Peris, Ketty
    Fangel, Stine
    Gjerum, Le
    Corriveau, Joshua
    Saeki, Hidehisa
    Warren, Richard B.
    Simpson, Eric
    Reich, Kristian
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (04) : 815 - 824
  • [40] Long-term, open-label safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: Final report of a 4-year study
    Adler, L. A.
    Spencer, T. J.
    Williams, D. W.
    Moore, R. J.
    Michelson, D.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S134 - S135
12345